Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.82 |
| ▸ | RAB9A | P51151 | 4/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | MLYCD | O95822 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | NQO1 | P15559 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10143992 | 0.91 | NPC1 (1.00) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL7166974 | 0.86 | MAPT (0.63) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL5703500 | 0.84 | HPGD (0.73) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL94674 | 0.83 | ALDH1A1 (0.68) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL1844719 | 0.83 | OPRM1 (0.67) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL9388919 | 0.83 | ALDH1A1 (0.66) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL27276866 | 0.83 | ALDH1A1 (0.60) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL13958531 | 0.82 | ALDH1A1 (0.59) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL31517003 | 0.82 | MAPT (0.63) | NPC1RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL8464986 | 0.81 | PARP10 (0.59) | NPC1RAB9AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511064-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| CN-100345843-C | 4- (thioxanthene-9-subunit) -piperidine or acridine derivative and application thereof in preparation of medicines | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2007-10-31 | — | — | CN | disclosed |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7060711-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-06-13 | — | — | US | disclosed |
| EP-1438307-B1 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2005-08-03 | — | — | EP | disclosed |
| CN-1575291-A | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2005-02-02 | — | — | CN | disclosed |
| EP-1438307-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | Biofrontera Pharmaceuticals GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1306376-A1 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | Biofrontera Pharmaceuticals AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003035646-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GMBH (DE) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | HTR2B, HTR1B, HTR3B | NPC1 2335/4885RAB9A 1375/4885ALDH1A1 547/4885 |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | HTR2B, HTR1B, HTR3B | NPC1 2335/4885RAB9A 1375/4885ALDH1A1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.